- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- October 2024
- 138 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- December 2024
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- January 2024
- 147 Pages
Global
From €4040EUR$4,250USD£3,394GBP
- Report
- June 2023
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- October 2021
- 77 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- December 2023
- 1362 Pages
Global
From €9502EUR$9,995USD£7,982GBP
- Report
- February 2024
- 75 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Book
- June 2021
- 400 Pages
Transcatheter mitral valve repair (TMVR) devices are specialized equipment used in minimally invasive procedures to treat mitral valve regurgitation, a common heart valve disease where blood flows backward into the left atrium because the mitral valve does not close tightly. These devices fall within the broader category of cardiovascular devices which encompass a range of products designed to treat various heart conditions. The TMVR market has developed as an alternative to conventional open-heart surgery, particularly for patients who are deemed at high risk for surgical complications. Different technologies are employed within this niche market, including those that enhance the coaptation of the mitral valve leaflets and those that aim to replace the dysfunctional valve entirely using a transcatheter approach.
The transcatheter approach offers benefits such as reduced recovery time and less trauma to the patient, making it a preferred option for certain cohorts. Advances in medical technology, an increase in the prevalence of mitral valve disorders, and a rising preference for minimally invasive techniques are among the factors that influence the adoption and development of TMVR devices.
Prominent companies in the TMVR market include Abbott Laboratories, which offers the MitraClip system. Edwards Lifesciences is noted for its developments in transcatheter heart valve therapies. Medtronic is another major player, with a portfolio that includes devices for various cardiac interventions. Boston Scientific and LivaNova also participate in this market, contributing to the diversity of available treatment options for mitral valve regurgitation and other Show Less Read more